Sentiment Stocks

$NWBO YouTube link to presentation. youtu.be/qOaodW6oK_o

@HollensbeAmanda Tell her that her smile is beautiful, as well as infectious… and that we love it! :)

Treatment #18 of 28 today. Just 10 more proton sessions to go. Then… London. Today we officially received confirmation of Braelyn’s pre-apheresis and leukapheresis appointments in the UK for DCVax immunotherapy. This is getting real. We are excited. We are nervous. We are hopeful. Today was also her second Avastin infusion. Some moments today were hard. The fatigue is real. The hair loss is accelerating. Radiation swelling continues to affect her speech and cognition at times. But she still finds ways to smile at me between all of it. I know these aren’t the best photos - she doesn’t always cooperate when I want to take her picture. But this is what fighting looks like sometimes. Exhaustion. Courage. Humor. Fear. Hope. All in the same room. And somehow, despite everything, we are now only weeks away from beginning the next phase we fought so hard to reach. June 1st. London. DCVax process begins! One day at a time. 💜 #BrainCancerAwarenessMonth #Glioblastoma #GBM #DCVax #DCvaxForBraelyn #ProtonTherapy #GrayMatterMatters

➡️A Settlement $NWBO The Case: Northwest Biotherapeutics, Inc v. Canaccord Genuity LLC, 1:22-cv-10185, (S.D.N.Y.) The Docket: courtlistener.com/docket/6657959… Recall, when I stated Canaccord Genuity was selling their market making division to Cantor and that could lead to a settlement as they would want to clean up before selling? See: x.com/hoffmann6383/s… Well, it happened. Just like TD settled their spoofing lawsuit prior to their Schwab sale. Here is $NWBO's recent court filing showing they have reached a settlement with Canaccord Genuity: See attached image. This should give $NWBO an infusion of cash. As a public company we should keep an eye on upcoming 10Q/10K filings to get an idea of the settlement amount.

Today was hard. Radiation #12 of 28. The doctors warned us this might happen—swelling from treatment can temporarily make symptoms worse. But knowing that doesn’t make it easier to watch. Her speech has gotten harder again. Words don’t come as easily. Today in speech therapy, she cried because she can feel the difference. And her hair is starting to thin on one side. She’s 18. And she is handling all of this with more strength than I can put into words. We’ve secured her next phase of treatment in the UK, and we’re so grateful to have that path forward. Now we’re working to make sure she can complete all phases of treatment over the next 24-36 months. If you feel led to share her story, it truly helps more than you know. 🤍 #BrainTumor #Glioblastoma #CancerSupport

Just bought the hard back! :) $NWBO amazon.com/dp/B0GXSYL4YT?…

Nice! $NWBO

@HollensbeAmanda I love how Braelyn approaches everything with a smile! :)

Braelyn Update Thursday April 9th Today felt like a turning point 🤍 Just a week ago, Braelyn needed help just to move her arm across a table. Today… she moved it on her own. She held on. She worked through every exercise. And her speech? Faster. Sharper. Stronger. She’s remembering, processing, responding in ways she couldn’t even days ago. I can’t even explain how big this is. We need her strong for what’s ahead—radiation, then the UK to begin treatment… and her Clemson Bridge program in the fall. Tonight, I feel hopeful 🤍 Thank you for walking this with us. (If you feel led to help or share, it truly makes a difference 🤍)

That's so wonderful to hear! Let's get young Amanda to live to a ripe old age! $NWBO

Tonight, people around Dehdasht provided an important help to the American pilot. By showing up in large numbers on the roads, they effectively blocked the ONLY POSSIBLE ground route for the Islamic regime’s forces to reach to the area the pilot had ejected on. I am so proud of these noble people❤️. With empty hands and their lives in their hands isolated with NO INTERNET FOR 36 days now, they are doing everything they can to support this military strike as it is the ONLY opening they can have to GET RID of this terrorist regime, which they can never get rid of unarmed AS THEY ARE. #FreeIran‌ #IranRevolution2026‌ #LongLiveIran_JavidShah

#dcvax $nwbo #gbm Launching 8 April: i4i PDA RWE NICE EVA funding opportunity Webinar: 15 April 2026, 1–2:30pm Gemini AI Analysis of importance, synergy and relevance to DCVax platform technology: 4. Strategic Timing "The timing of this call (opening April 2026) aligns with the expected progression of DCVax-L through the UK regulatory system. As the technology moves from "In Development" to a formal NICE decision, a "conditional" recommendation for early use (the EVA) would make it eligible for this multi-million-pound funding stream to support its rollout across NHS trusts" (Gemini AI Analysis - continued below) The link provided refers to a specific National Institute for Health and Care Excellence (NICE) Early Value Assessment (EVA) and a related funding call from the National Institute for Health and Care Research (NIHR). Specifically, the NIHR i4i PDA RWE NICE EVA (Invention for Innovation, Product Development Award, Real-World Evidence) is a specialized funding stream designed to bridge the "evidence gap" for promising medical technologies.The importance and synergy of this specific funding and regulatory framework to the DCVax platform technology (Northwest Biotherapeutics) are significant. Below is an analysis of how these elements intersect:1. Importance: Bridging the "Evidence Gap"The primary hurdle for personalized immunotherapies like DCVax-L is moving from clinical trial success to routine National Health Service (NHS) reimbursement.The Funding's Purpose: This NIHR call specifically funds the collection of Real-World Evidence (RWE). This is data gathered from patients treated in everyday clinical practice rather than a strictly controlled trial.Relevance to DCVax: Since DCVax-L has already shown significant survival benefits in its Phase III trial, the next hurdle is "commissioning." NICE often issues "conditional recommendations" through the EVA process, meaning they believe the tech is promising but need more data on cost-effectiveness and long-term real-world performance before full rollout. This funding allows companies to gather that data without the financial burden falling entirely on the developer or the individual NHS trusts.2. Synergy: NICE EVA and DCVax’s PotentialThe NICE Early Value Assessment (EVA) is a rapid review process for innovative technologies that address unmet needs.Accelerated Access: If DCVax-L were to enter the EVA pathway, it could receive a recommendation for use in the NHS while further evidence is being generated. This creates a "synergy" where patients get access years earlier than the traditional multi-year NICE appraisal process.Platform Potential: DCVax is not just a single drug; it is a platform technology. Because it uses the patient's own tumor antigens, it can theoretically be adapted for any solid tumor (Direct, Prostate, etc.). A successful RWE project for Glioblastoma (the lead indication) creates a regulatory and evidentiary "blueprint" that could be applied to other cancers in the DCVax pipeline.3. Relevance: The Strategic "Fit"The April 2026 funding call is highly relevant to DCVax for three reasons:Cost-Effectiveness: Personalized medicines are expensive to manufacture. The NIHR/NICE synergy focuses heavily on "health economic cases." This funding supports the creation of the economic models required to prove that the high upfront cost of DCVax is offset by long-term survival and reduced need for end-of-life care.Analytical Partnerships: The call requires an "Analytical Partner" (usually a university or specialist CRO) to lead the evidence generation. This is ideal for a mid-sized biotech like Northwest Biotherapeutics, as it provides external validation of their data by UK academic institutions.UK as a Testbed: The UK's Life Sciences Vision aims to make the NHS a "leading testbed" for late-stage innovations. For a US-based company like Northwest Biotherapeutics, utilizing this UK framework provides a "gold-standard" stamp of approval from NICE, which is often used as a benchmark by other international health regulators. In short, the April 2026 call represents a commercial and regulatory "on-ramp" for the DCVax technology to move from a successful clinical trial asset to a standard-of-care treatment within the UK healthcare system. nihr.ac.uk/funding/i4i-pd… he NIHR funding call you referenced (i4i PDA RWE NICE EVA April 2026) has high theoretical relevance to Northwest Biotherapeutics' DCVax® platform technology, specifically because it is designed to fund the exact type of evidence generation that DCVax-L currently requires for UK adoption. Here is the breakdown of why this is relevant: 1. The Funding Purpose: Filling the "Evidence Gap" The specific aim of this NIHR (National Institute for Health and Care Research) call is to provide funding for technologies that have received a NICE Early Value Assessment (EVA) recommendation. What it does: It funds the generation of Real-World Evidence (RWE) to address uncertainties identified by NICE. Relevance to DCVax: DCVax-L is currently undergoing a NICE Single Technology Appraisal (ID836) for treating glioblastoma. If NICE decides that the current clinical trial data is promising but needs more "real-world" validation before a full recommendation, they often move the technology into the EVA pathway. This NIHR grant would then be the primary mechanism to pay for that data collection within the NHS. 2. Alignment with DCVax’s Regulatory Status The DCVax platform is a personalized immunotherapy. For such "disruptive" technologies, health regulators like NICE often struggle with "long-tail" data—how patients fare over many years in a standard hospital setting compared to a controlled trial. The NIHR call explicitly asks for analytical partners and technology partners (like NW Bio) to team up with NHS adopting sites. This matches NW Bio’s stated strategy of seeking ways to make DCVax available to UK patients through the NHS while simultaneously collecting the data required for full reimbursement. 3. Addressing the "Health Economic Case" A major hurdle for DCVax has been the cost-benefit analysis (Health Economics). This NIHR call specifically requires applicants to: Outline a clear health economic case. Describe how the technology reduces mortality or improves quality of life compared to existing NHS pathways (e.g., the Stupp Protocol). Funding from this grant (up to 36 months) would allow the company to prove that DCVax reduces the long-term burden on the NHS, potentially justifying its price point. 4. Strategic Timing The timing of this call (opening April 2026) aligns with the expected progression of DCVax-L through the UK regulatory system. As the technology moves from "In Development" to a formal NICE decision, a "conditional" recommendation for early use (the EVA) would make it eligible for this multi-million-pound funding stream to support its rollout across NHS trusts. In short: This funding is a "bridge" to help expensive, innovative technologies like DCVax get over the final hurdle of NHS cost-effectiveness hurdles by paying for the necessary real-world data collection

@DCVaxDefender @IDoLoveNZ1 @LessIsM14781097 @sharpie510 Agree completely! :) $NWBO

@IDoLoveNZ1 @LessIsM14781097 @sharpie510 No, it suggests management are positioning $NWBO well before news as this coverage shows up on Bloomberg terminal and other outlets. The arguments made in the 70 page report are valid thus a starting point for future analysts to digest after news hits the wire.

First Berlin Equity Research on 24/03/2026 initiated coverage on Northwest Biotherapeutics Inc. (ISIN: US66737P6007 / Bloomberg: NWBO US). Analyst Christian Orquera placed a BUY rating on the stock, with a USD 1.00 price target. $nwbo #dcvax markets.ft.com/data/announce/…

@ThomasOwenMcCa1 Great news, Thomas! It’s been a rough week, losing two good men who’ve been a part of this battle, so you celebrating 11 years of GBM survival is wonderful news. Congrats! :)

Today was a big Milestone for me, I celebrated my 11th year anniversary of my grim diagnosis of a Glioblastoma Multiforme. I was administered the DCVax in 2015. The Clinical Trial has been going for the better part of 3 decades. I know this because @ a recent fundraiser for @UCLANeurology , I met him, he’s a firefighter who survived 26 years. I should have been happy, but instead I’m angry. Angry at Wall Street & Big Pharma for suppressing a Cure for the MOST AGGRESSIVE FORM OF CANCER & all solid form tumor’s. I put the lion’s share of the blame on KENNETH C. Griffin the Greediest C.E.O of @citsecurities A Market Maker on Wall Street. You remember Bernie Madoff, yep the guy who attempted one of the biggest PONZI SCHEMES IN AMERICAN HISTORY. Well guess what folks, KENNETH C. GRIFFIN LEARNED ALL HIS DIRTY TRICKS FROM HIM. (Payment for Order flow.) The only difference MADOFF TRIED TO SCAM CELEBRITIES. Kenny scammed RETAIL INVESTORS, the difference; people support CELEBRITIES. They don’t CARE ABOUT RETAIL INVESTORS… It’s all about Profits, they could CARE LESS ABOUT PATIENTS LIVES, they can sleep at night knowing that they LITERALLY SENT PEOPLE to be poisoned by antequated S.O.C’s (I.E Chemotherapy& Radiation ☢️.) The NWBO Longs has SUFFERED great losses, just in the last week. R.I.P Todd WIllever, a Valiant Firefighter who hailed from Trenton N.J, R.I.P @metacollectiveG a STRONG Advocate & E.R Dr. who generously gave his time & Wisdom to anyone. He passed away in his SLEEP? You may think you won but with every passing we GET STRONGER… I want to say a big heart FU$K OFF TO ALL THE EMPLOYEES OF @citsecurities YOU ARE ALL COMPLICIT IN THE MASS MURDER’s of Kids, teenagers, adults & the elderly. Big Pharma YOU ARE JUST AS GUILTY. I wish nothing less than a world of pain for you sociopaths… @NorthwestBio @LisainNJUSA @LindaZivic @ElvirPons @andrewcaravello @kshaughnessy2 @JackAWynn @NYMag FUCK @adamfeuerstein FUCK @statnews you tabloid wannabe Scum… FU&k @MarkBurnettTV for giving THE ORANGE 🍊 PEDO a platform… @LastWeekTonight @TheLastWord R.I.P @Clairotonin R.I.P Mike Murray R.I.P Mike Murray R.I.P Anne Kelly R.I.P Michael Richmond & all the countless lives LOST to this horrible “Orphan Disease”… & Last but not least, FU$K the New Owner of @twitter You’re a FASCIST. You didn’t invent JACK 💩, Oh and FU$K @PalantirTech you are all a collection of SOULLESS GHOULS… #FU$KA.I You can’t steal artists work… NWBO DCVax Is the Future of Personalized Immunotherapy… It’s only a matter of time. Tick Tick Kenny C. Griffin better finish up that construction on THAT BILLION DOLLAR 💵 PROPERTY YOUR BUILDING IN PALM BEACH 🏝️ FLORIDA YOU SHAMELESS PRICK. Last time I checked LYING 🤥 UNDER OATH WAS AGAINST THE LAW. Better get your affairs in order. Shame on @Harvard you take Kenny’s blood 🩸 money & name a building after. How can you call yourself a philanthropist when you give away 300 million, when you make BILLIONS? That’s Rich… Dr. Linda Liau, Deserves the Nobel Peace Prize 🏆NUFF SAID!!!

The company’s highest priority has been at all times to address any question the MHRA might pose, and $NWBO has stated just that (at the ASM). On the other hand, the entire UK regulative process appears to have been - unfortunately - more like moving through a thick bureaucratic sludge, IMO.

@smith348572 @Dave46217976 @MHRAgovuk One plausible reason for the long process could be that there was an inordinate amount of “stoppage time” for the company to address questions posed by the MHRA. Would it surprise us that the company was slow in this regard?

$NWBO Dear @MHRAgovuk ,  You have to explain to me how a therapy that: 1Shows no meaningful toxicity or serious side effects, 2Demonstrates 13.5% five-year overall survival versus about 5% with the current standard of care, 3Has GMP manufacturing already approved at the Sawston facility (December 2025), 4Was supported by Phase 3 trial results published in @JAMAOncology, 5Targets a disease where no meaningful new therapy has been approved for glioblastoma in more than 20 years can still remain unapproved after more than two years of regulatory review. My concern is not about the therapy itself. The data exist, the safety profile is clear, and the manufacturing capability has already been authorized. The real concern is the inefficiency and heavy bureaucracy within the MHRA process. $NWBO also has a large and highly engaged community following this application. Many people—patients, families, physicians, and investors—are carefully examining every step of this process and trying to understand why a decision continues to be delayed. Given the circumstances, it is natural that people begin asking what the real reason is for the prolonged delay, especially when there are well-known financial interests that have publicly worked against this company for years. At some point, transparency becomes necessary. @Siobhain_Mc @wesstreeting @Nigel_Farage @Keir_Starmer

@justinkeister5 @smith348572 @Siobhain_Mc @MHRAgovuk @wesstreeting @Keir_Starmer @InstituteGC So true… it’s just the start!

@smith348572 @Siobhain_Mc @MHRAgovuk @wesstreeting @Keir_Starmer @InstituteGC Further, survival using #DCVAX shows the potential to improve further using better agonist therapies. 13% is a start.

Phil Woolas, Littleborough and Saddleworth MP 1997- 2010 passed away last night. A lovely man&very able colleague. Last time I saw him was June 2024 at the Glioblastoma Drug trial fundraiser in memory of my sister. Last night the same disease took his life. We will find a cure!

@HollensbeAmanda Next she’ll be walking the runway! :)

Braelyn update Friday 3/13 Today felt like a big step forward. Braelyn was finally able to shower and wash her hair (with help from Mom), and she was very happy to trade hospital pajamas for real clothes again. She’s been eager to walk and even went down 20 stairs today with one railing and minimal assistance from mom. Tonight she will finally transfer to an inpatient rehabilitation facility where she’ll begin intensive therapy to regain strength, speech, and independence. We are especially grateful that this facility will allow Braelyn to continue taking her seizure medications exactly as she has been at home, which is critical for her seizure control. Several of Braelyn’s doctors here at UCLA were surprised and disappointed that another highly ranked rehab facility would not accept her unless we agreed to change the formulation of her seizure medication — something that previously caused a significant increase in seizures. Thankfully, we have now found a place willing to work with Braelyn’s medical needs. We’re grateful to finally move forward with rehab and the hard work of recovery. 🤍

So VERY sorry to hear of Todd's passing. Between your warrior husband and Greg Z., these past two days have been a kick to the gut. "Cowards shrink from challenges, weaklings flee from them, but warriors wink at them." ~ Matshona Dhliwayo It might be comforting to think that Todd is winking still.

$NWBO #DCVAX It is with unbearable sorrow that I share with you that my warrior husband, Todd, was rushed to the ER Saturday with double pneumonia/sepsis. It was too much for his body. After 46 #GBM months, he passed early Sunday, waiting for our son/DIL to return from Italy.🥺

@HollensbeAmanda @LisainNJUSA Braelyn already looks so much better… healthier, beautiful. You can do this girl! ❤️

Post-op day 4 update on Braelyn. Today brought some real progress. • The swelling around her eye is improving and she can open her left eye again. • She walked about 50 feet with assistance — a big improvement since surgery. • Her speech is a little better and she was able to read simple sentences aloud. She still struggles to express her needs and thoughts, but that too is slowly improving. We also caught a UTI early, so she started antibiotics today. Now we’re waiting for insurance approval and a rehab bed so she can begin intensive therapy. In the meantime, she’s stuck doing PT, OT, and speech practice with Mom in the hospital as much as she’ll tolerate. Small steps. Real progress. One day at a time. Keep cheering Braelyn on — she feels the love. 🤍

@MHRA it's time to quit pushing paper for $NWBO's #DCVax-L (side to side and up and down?) and to instead start saving your UK #GBM lives.

It's probably worth noting that Dr. Aiken is treating patients with a dendritic cell therapy (using the patient's own manufactured dendritic cells) that's loaded with mRNA and proteins from freshly obtained patient tumor specimens (through Diakonos Oncology). Will those "tumor specimens" cover all the droves of proteins, antigens, etc., found on the patient's individual tumor like $NWBO's #DCVax-L does? Answer: Probably not. atlantichealth.org/press-releases…

$NWBO listening to Dr. Aiken on the Musella Webinar (45m mark), he basically said DCVax-L will never see the light of day in the U.S. and called the tech old (1st gen) and said we’re now on 3rd or 4th gen. @andrewcaravello @metacollectiveG, thoughts? Can he really be that wrong?

Will the DC vaccine be loaded with a lysate from her OWN tumor -which will alert the T cells to know EXACTLY what to look for? #DCVax-L has not only your own DCs, but it also comes primed with your own tumor antigens, which is MUCH better than simply injecting your own lab grown DCs into your body.

@HollensbeAmanda Braelyn will have own personalized cancer immunotherapy. Not only will these lab-grown dendritic cells activate killer T cells & destroy the tumor, they’ll also train the immune system to recognize any future tumor cells & destroy them as well.

Update from UCLA 🧵 Dr. Liau reviewed Braelyn’s scans. What looks like a “two-piece snowman” is likely one large tumor with multiple lobes. Her midline shift has increased from 11mm to 19mm — significant growth despite max steroids. (A thread)